Novartis AG
- Open
- 156.59
- Day high
- 158.08
- Day low
- 155.77
- Prev close
- 155.01
- Volume
- 904K
- Mkt cap
- $298.9B
- P/E (TTM)
- 23.5
- EPS (TTM)
- $6.66
- P/B
- 7.2
- P/S
- 5.4
- Yield
- 1.97%
- Per share
- $3.08
Novartis AG (NVS) is a Healthcare company listed on NYSE. The stock is up 32% over the past year. Drillr has 1 published research article covering NVS.
Novartis AG (NVS) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
NVS earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Jul 21, 2026 | $2.17 | $2.41 | +11.1% | $14.4B | +2.4% |
| Apr 28, 2026 | $2.11 | $1.99 | -5.7% | $13.1B | -2.4% |
| Feb 4, 2026 | $1.99 | $2.03 | +2.0% | $13.3B | +0.1% |
| Jul 17, 2025 | $2.38 | $2.42 | +1.7% | $14.3B | +2.5% |
| Jan 31, 2025 | $1.80 | $1.98 | +10.0% | $13.6B | +5.6% |
| Jul 18, 2024 | $1.89 | $1.97 | +4.2% | $12.5B | -0.2% |
| Jan 31, 2024 | $1.64 | $1.53 | -6.7% | $11.8B | -0.9% |
| Jul 18, 2023 | $1.68 | $1.83 | +8.9% | $13.9B | +3.4% |
| Feb 1, 2023 | $1.42 | $1.51 | +6.3% | $13.1B | -1.0% |
| Jul 19, 2022 | $1.51 | $1.56 | +3.3% | $13.1B | +1.6% |
| Feb 2, 2022 | $1.44 | $1.40 | -2.8% | $13.5B | +1.5% |
| Jul 21, 2021 | $1.53 | $1.66 | +8.5% | $13.3B | +2.6% |
Novartis AG company profile
Overview
Novartis AG (NYSE:NVS) is a Swiss multinational pharmaceutical corporation founded in 1996 through the merger of Ciba-Geigy and Sandoz. Headquartered in Basel, Switzerland, Novartis has evolved into one of the world's largest pharmaceutical companies, focusing on innovative prescription medicines across multiple therapeutic areas. The company completed a significant strategic transformation in 2023 by spinning off its generics division Sandoz, allowing it to focus entirely on developing and commercializing breakthrough treatments for serious diseases.
Business
Novartis operates as a research-based pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines for patients with serious medical conditions. The pharmaceutical industry involves the lengthy and expensive process of drug discovery, where companies identify promising compounds, test them through multiple phases of clinical trials over many years, and seek regulatory approval before bringing medicines to market. The company's business is now structured around a single segment called Innovative Medicines, which represents virtually 100% of revenue following the 2023 Sandoz spin-off. This segment focuses on developing and commercializing novel prescription drugs across five core therapeutic areas: 1. Cardiovascular and Metabolism: Led by Entresto, a heart failure treatment that generated $7.8 billion in 2024 sales. This area addresses conditions like heart failure, high cholesterol, and metabolic disorders. 2. Immunology and Dermatology: Anchored by Cosentyx, a treatment for autoimmune conditions like psoriasis and ankylosing spondylitis, which achieved over $6 billion in 2024 sales. 3. Neuroscience: Featuring Kesimpta, a multiple sclerosis treatment that reached $3.2 billion in 2024 sales, addressing neurological and psychiatric conditions. 4. Oncology: Including Kisqali for breast cancer ($3 billion in 2024) and Pluvicto, a radioligand therapy for prostate cancer ($1.4 billion in 2024). This area focuses on cancer treatments using both traditional and cutting-edge approaches. 5. Ophthalmology: Developing treatments for eye diseases and vision disorders. The company also operates three technology platforms: radioligand therapy (using radioactive particles to target cancer cells), cell and gene therapy (modifying patients' cells or genes to treat disease), and RNA therapeutics (using RNA molecules to influence protein production).
Revenue model
Novartis generates revenue primarily through direct sales of prescription medicines to healthcare systems, hospitals, pharmacies, and patients worldwide. The company's business model relies on developing proprietary drugs protected by patents, allowing it to charge premium prices during the exclusivity period before generic competition emerges. The company's customers include healthcare providers, hospitals, specialty pharmacies, and government health systems. In many markets, Novartis negotiates pricing and reimbursement with government health authorities and insurance companies who ultimately pay for the medicines. The company also increasingly works directly with patients through specialty pharmacies and patient assistance programs. Several factors significantly impact Novartis's profitability margins. Positive margin drivers include successful drug launches that command high prices due to their clinical benefits, patent protection that prevents generic competition, and operational efficiency improvements in manufacturing and sales processes. The company has demonstrated strong margin expansion, reaching a core operating margin of 38.7% in 2024, with targets to reach 40% by 2027. Negative margin pressures come from multiple sources. Generic competition severely impacts revenue when patents expire, as seen with upcoming patent losses for Entresto, Tasigna, and Promacta in 2025. Regulatory pricing pressures, particularly from government health systems seeking to control healthcare costs, continuously squeeze margins. The U.S. Inflation Reduction Act, which allows Medicare to negotiate drug prices, represents a significant headwind. Additionally, the substantial costs of drug development - often exceeding $1 billion per approved drug - and the high failure rates in clinical trials create ongoing margin pressure. Manufacturing complexity, particularly for advanced therapies like radioligand treatments, also increases costs.
Competitive moat
Novartis possesses a moderately strong competitive moat built primarily on its extensive patent portfolio, regulatory expertise, and specialized manufacturing capabilities. The company's patent protection provides temporary monopolies on its key drugs, allowing premium pricing during exclusivity periods. However, this protection is inherently time-limited, typically lasting 10-15 years from drug approval. The company's strongest moat elements include its deep expertise in complex therapeutic areas like radioligand therapy, where manufacturing requires specialized facilities and know-how that create barriers to entry. Novartis has invested heavily in building manufacturing capabilities for advanced therapies, including a $23 billion commitment to U.S. manufacturing infrastructure. The company's established relationships with healthcare providers, regulatory agencies, and payers across global markets also provide competitive advantages. However, the moat faces significant vulnerabilities. Patent cliffs represent the most immediate threat, with major revenue losses expected as key drugs lose exclusivity. The pharmaceutical industry's high R&D costs and lengthy development timelines mean that maintaining the innovation pipeline requires continuous investment with uncertain returns. Generic and biosimilar manufacturers can quickly erode market share once patents expire, as demonstrated by typical revenue declines of 80-90% following generic entry. Competitive threats come from multiple directions. Large pharmaceutical companies like Pfizer, Roche, and Johnson & Johnson compete directly across most therapeutic areas. Biotechnology companies increasingly challenge established players with novel approaches. Additionally, regulatory pressure for lower drug prices, particularly from government health systems, continuously threatens pricing power. The company's moat is best described as renewable but requiring constant investment to maintain through continuous innovation and successful drug development.
Risks & safety
Novartis demonstrates a strong financial safety profile with solid cash generation and manageable debt levels, though some liquidity metrics warrant attention. • **Cash and Liquidity**: $11.5 billion in cash and short-term investments as of Q4 2024, with strong free cash flow generation of $13.8 billion annually. Operating cash flow of $17.6 billion provides substantial cushion. • **Debt Management**: Debt-to-equity ratio of 0.71 is reasonable for a large pharmaceutical company. Total liabilities of $58.1 billion against total assets of $102.2 billion shows solid balance sheet structure. • **Solvency Concerns**: Current ratio of 1.04 indicates tight short-term liquidity, with current assets barely covering current liabilities. Quick ratio of 0.84 suggests potential working capital management challenges. • **Valuation Metrics**: Trading at 16.4x earnings and 4.5x book value, with EV/EBITDA of 10.4x. These metrics suggest reasonable but not cheap valuation levels. • **Other Considerations**: Strong ROE of 27% indicates efficient capital allocation. Predictable dividend payments and share buyback programs demonstrate commitment to shareholder returns. Patent cliff risks for major drugs create medium-term revenue uncertainty despite strong current cash flows.
Recent development
Over the past few years, Novartis has executed a comprehensive strategic transformation focused on becoming a pure-play innovative medicines company. The most significant move was the 2023 spin-off of Sandoz, the generics division, allowing management to concentrate entirely on high-value prescription drugs. The company has pursued an aggressive portfolio optimization strategy, narrowing its focus to five core therapeutic areas while divesting non-core assets. This includes a $23 billion investment commitment to expand U.S. manufacturing and R&D capabilities, aiming to produce 100% of key U.S. products domestically. Management has also implemented productivity programs targeting $1.5 billion in cost savings. Pipeline advancement has been particularly strong, with multiple breakthrough approvals including Kisqali's expansion into early breast cancer, Fabhalta's accelerated approval for IgA nephropathy, and Pluvicto's continued expansion in prostate cancer. The company has achieved over 10 positive Phase III readouts across recent years, with key upcoming catalysts including Scemblix's first-line CML approval and multiple new indication expansions for existing drugs. The company has also made strategic technology platform investments, particularly in radioligand therapy where it's building a comprehensive portfolio beyond Pluvicto. Recent acquisitions include votoplam for Huntington's disease and continued development of cell and gene therapy capabilities. Management has indicated willingness to pursue bolt-on acquisitions under $5 billion in core therapeutic areas. Regulatory and policy engagement has become increasingly important, with active advocacy around drug pricing policies, particularly regarding the U.S. Inflation Reduction Act and European pricing pressures. The company is working to extend small molecule exclusivity periods and address other policy challenges affecting pharmaceutical innovation.
NVS company profile · for informational purposes only — not investment advice.
Track NVS with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free